Charles River Laboratories International Inc. CRL
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Charles River Laboratories International Inc. shares you hold and we'll calculate your dividend payments:
Sign up for Charles River Laboratories International Inc. and we'll email you the dividend information when they declare.
Add Charles River Laboratories International Inc. to receive free notifications when they declare their dividends.
Your account is set up to receive Charles River Laboratories International Inc. notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Charles River Laboratories International Inc. dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0c | — |
| 2007 | 0.0c | 0% |
| 2008 | 0.0c | 0% |
| 2009 | 0.0c | 0% |
| 2010 | 0.0c | 0% |
| 2011 | 0.0c | 0% |
| 2012 | 0.0c | 0% |
| 2013 | 0.0c | 0% |
| 2014 | 0.0c | 0% |
| 2015 | 0.0c | 0% |
| 2016 | 0.0c | 0% |
| 2017 | 0.0c | 0% |
| 2018 | 0.0c | 0% |
| 2019 | 0.0c | 0% |
| 2020 | 0.0c | 0% |
| 2021 | 0.0c | 0% |
| 2022 | 0.0c | 0% |
| 2023 | 0.0c | 0% |
| 2024 | Sign Up Required | |
Charles River Laboratories International Inc. Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 22 November 2023
- 52 Week Low
- 0.0% on 22 November 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Charles River Laboratories International Inc.
Charles River Laboratories International, Inc. is a full service, non-clinical contract research company. The Company provides research models required in research and development of new drugs, devices, and therapies. The Company's segments include Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the research models, research model services, and research and GMP-compliant cells businesses. The DSA segment includes services required to take a drug through the early development process, including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions (Biologics), and Avian Vaccine Services (Avian).
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United States
- Share Price
- $187.90 (yesterday's closing price)
- Shares in Issue
- 51 million
- Market Cap
- $9.6bn
- 0
- Market Indices
- S&P 500
- Home Page URL
- https://www.criver.com/
